Drugs that contain Ponesimod

1. Drug name - PONVORY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(2 years from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

CN100567275C JANSSEN PHARMS As Immunosuppressive Agents 5 - (Phenyl - (Z) - Ylidene)--4 - Ketone Derivative
Nov, 2023

(1 year, 1 month from now)

CN1882555A JANSSEN PHARMS As Immunosuppressant 5 - (Phenyl - (Z) - Subyl) - Thiazole - -4 - Ketone Derivative
Nov, 2023

(1 year, 1 month from now)

CN102177144A JANSSEN PHARMS Crystalline Forms Of (R)-5-[3-Chloro-4-(2,3-Dihydroxy-Propoxy)-Benz[Z]Ylidene] -2- ([Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

CN102177144B JANSSEN PHARMS (R)-5-[3-Chloro--4-(2, 3-Dihydroxy-Propoxy)-Benzo [Z] Subunit]-2-([Z]-Propyl)--3-O-Tolyl--4-Ketone Of Crystal Form
Oct, 2029

(7 years from now)

IN254201B JANSSEN PHARMS Novel Thiazolidin-4-One Derivatives
Nov, 2024

(2 years from now)

IN200602225P4 JANSSEN PHARMS Novel Thiazoldin-4-One Derivatives
Nov, 2024

(2 years from now)

EP1689726A1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

EP1689726B1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

EP2344465B1 JANSSEN PHARMS Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

EP2344465A1 JANSSEN PHARMS Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives Nov, 2024

(2 years from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives Dec, 2025

(3 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist Dec, 2035

(13 years from now)

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.